BioMark Diagnostics Inc.
BMKDF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -5.5% | 6.3% | 249.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -949.6% | -563.1% | -876.8% | -2,787.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,249.7% | -874.5% | -1,200.2% | -3,309.4% |
| EPS Diluted | -0.02 | -0.017 | -0.022 | -0.02 |
| % Growth | -19.8% | 25.1% | -10.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |